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Abstract
Background: To preclude transfer of aneuploid embryos, current preimplantation genetic screening (PGS) usually
involves one trophectoderm biopsy at blastocyst stage, assumed to represent embryo ploidy. Whether one such
biopsy can correctly assess embryo ploidy has recently, however, been questioned.
Methods: This descriptive study investigated accuracy of PGS in two ways. Part I: Two infertile couples donated
11 embryos, previously diagnosed as aneuploid and, therefore, destined to be discarded. They were dissected into
37 anonymized specimens, and sent to another national laboratory for repeat analyses to assess (i) inter-laboratory
congruity and (ii) intra-embryo congruity of multiple embryo biopsies in a single laboratory. Part II: Reports on
human IVF cycle outcomes after transfer of allegedly aneuploid embryos into 8 infertile patients.
Results: Only 2/11 (18.2 %) embryos were identically assessed at two PGS laboratories; 4/11 (36.4 %), on repeat
analysis were chromosomally normal, 2 mosaic normal/abnormal, and 5/11 (45.5 %) completely differed in reported
aneuploidies. In intra-embryo analyses, 5/10 (50 %) differed between biopsy sites. Eight transfers of previously
reported aneuploid embryos resulted in 5 chromosomally normal pregnancies, 4 delivered and 1 ongoing. Three
patients did not conceive, though 1 among them experienced a chemical pregnancy.
Conclusions: Though populations of both study parts are too small to draw statistically adequately powered
conclusions on specific degrees of inaccuracy of PGS, here presented results do raise concerns especially about
false-positive diagnoses. While inter-laboratory variations may at least partially be explained by different diagnostic
platforms utilized, they cannot explain observed intra-embryo variations, suggesting more frequent trophectoderm
mosiaicsm than previously reported. Together with recentl published mouse studies of lineages-specific degrees of
survival of aneuploid cells in early stage embryos, these results call into question the biological basis of PGS, based
on the assumption that a single trophectoderm biopsy can reliably determine embryo ploidy.
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Background
Human embryos are frequently aneuploid. The preva-
lence further increases with advancing female age and
with low functional ovarian reserve (LFOR) [1]. Avoid-
ing transfers of aneuploid embryos in association with
in vitro fertilization (IVF) has been proposed since the
early 1990s [2] under the assumption it would lead to
better pregnancy rates and fewer miscarriages [3]. This
effort was given the acronym preimplantation genetic
screening (PGS) but over almost two decades has
failed to demonstrate promised improvements of in
vitro fertilization (IVF) outcomes.
Initial criticisms of the procedure [4–7] were attrib-
uted to technical shortcomings of initial cleavage-stage
embryo biopsies and inadequate techniques of chromo-
somal analyses [8]. Once embryo biopsy moved from
cleavage- to blastocyst-stage (trophectoderm), and
selected chromosome investigation to full chromosomal
complement analyses with highly accurate newly devel-
oped diagnostic platforms, the widely held assumption
was that PGS, finally, would show its clinical effective-
ness. When this did not happen, the ability of different
PGS platforms to accurately determine embryo ploidy
was questioned [9].
Observing in clinical practice statistically improb-
able high aneuploidy rates, especially in some younger
women, The Center for Human Reproduction (CHR)
decided in 2014 to offer women with only aneuploid
embryos embryo transfers with allegedly aneuploid
embryos in selected cases [10], an effort quickly joined
by other fertility centers, leading to the establishment
of the International PGS Consortium, dedicated to
investigations of effectiveness of PGS in association
with IVF.
The Consortium since reported 3 chromosomally
normal live births from 5 such transfers [11]. Concomi-
tantly, an Israeli member of the International PGS
Consortium completed a PGS study of embryos with
single gene diseases, reporting significant discrepancies
between multiple trophectoderm and inner cell mass
biopsies (Prof. Raoul Orvieto, personal communication,
New York, October 2015). This study has since been
published [12]. Shortly thereafter, Italian colleagues
reported on 18 attempts of transfer of “mosaic” (i.e.,
aneuploidy) embryos in women who had produced no
euploid embryos in IVF cycles, establishing 6 chromo-
somally normal live births (33.3 %) [13].
This manuscript now raises additional doubts
about the ability of PGS to accurately determine
embryos ploidy by reporting significant inter-
laboratory and intra-embryo discrepancies for PGS
results as well as two additional normal pregnancies
established from transfer of embryos previously
designated as aneuploid.
Methods
Here reported study received Institutioanl Review Board
(IRB) approval ER 10232015:01 at The Center for
Human Reproduction.
PGS laboratories and PGS platforms
The CHR received 11 donated embryos for Part 1 of
here reported manuscript. These embryos had previ-
ously at two national referral laboratories of inter-
national repute (both laboratories have extensively
contributed to the PGS literature) been reported as
aneuploid: Reprogenetics (Livingston, N.J., now a div-
ision of Cooper Surgical, Trumbull, CT) served one
couple utilizing array CGH [14], and the not-for-profit
Foundation for Embryonic Competence (FEC), utilizing
an in-house developed test, called Select Comprehen-
sive Chromosome Screening (CCS) based on real-time
polymerase chain reaction (qPCR) technology, developed
by Reproductive Medicine Associates of New Jersey
(Basking Ridge, N.J.) [15] served the other couple.
Specimen preparation and coding
All donated embryos investigated in this study were do-
nated to The Center for Human Reproduction (CHR).
Most were donations of the center’s own patients but
some were donated by a couple that had their embryos
stored at another Consortium member’s laboratory.
CHR received these embryos cryopreserved and with full
documentation of PGS results from the original IVF cen-
ter. They were maintained in standard liquid nitrogen
tanks until dissection of all 11 embryos into 37 individ-
ual specimens (1–5 per embryo, depending on technical
feasibility) by one of the authors (C.H.) Fragmentation of
embryos was achieved utilizing standard laser-assisted
dissection instrumentation, as is routinely utilized for
trophectoderm biopsies during PGS.
In mimickery routine, the 37 specimens were randomly
coded as 4 patients (in Table 1, A1-A8, B1-B8, C1-C10 and
D1-D11) and sent to a third national PGS laboratory (IVI-
GEN, Miami, FL). This laboratory used for 24-chromosome
assessment comparative genomic hybridization (aCGH,
BlueGnome, 24sure BAC-based arrays), in more detail de-
scribed at: http://www.cytochip.com.
The laboratory was aware that submitted specimens
involved a research project, but was uninformed about
details and purpose of the project. Specimen codes were
broken upon receipt of results, at which time inter-
laboratory and intra-embryo/laboratory discrepancies
were determined.
Embryo transfers
Transfers of supposedly chromosomally abnormal)
embryos were performed at three independent fertility
centers in New York City, CHR, Fertility Specialists in
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New York and Braverman IVF & Reproductive Immun-
ology. CHR developed and published in 2014 a policy,
since also adopted by the other IVF centers [10], which
with appropriate and detailed informed consent allowed
transfer of selected supposedly aneuploid embryos if no
or only inadequate numbers of euploid embryos were
available for transfer.
Statistical considerations
Because of small numbers of involved patients and em-
bryo specimens, statistical comparisons and determina-
tions of assciations were not possible. Since embryos
diagnosed to be aneuploid usually, however, are ethically
discarded, reported live births after transfer of such
embryos categorically reflect otherwise unachievable
outcomes.
Results
Table 1 summarizes the chromosomal abnormalities of
11 embryos in their original testing round, and in their
subsequent repeat evaluation, dissected into 1–5
fragments.
Outcome comparison between PGS laboratories
Only 2/11 (18.2 %) of embryos demonstrated congruent
results between both laboratory evaluations: embryo A2-
A4 and D8-D11. Most remarkably, 4/11 (36.4 %) of
embryos, originally reported as abnormal, on repeat as-
sessment were found to be normal 46, XX or 46, XY
embryos (A1, C1-C3, C4-C6 and C7-C10). An additional
2 embryos, at least in some biopsies demonstrated nor-
mal karyotypes (A6 and A8, B8). Combined, 6/11
(54.6 %) embryos upon retesting were either definitely
normal or mosaic with potential to be normal, thus of-
fering potential pregnancy chances if transferred. Even
where both laboratories agreed that embryos were chro-
mosomally abnormal, there was complete congruence
between both laboratories in only 1/11 (9.1 %) embryos
(D8-D11). Remarkably, even sex chromosome identifica-
tions were apparently inaccurate since they varied be-
tween laboratories.
Intra-embryo variation based on multiple biopsies
Among 10 embryos where more than one biopsy was
submitted for PGS in the second testing round, 5 (50 %)
offered congruent results on 2–4 biopsies (B1-B4, C1-
C3, C4-C6, C7-C10 and D8-D11). All other embryos,
even in the same PGS laboratory, demonstrated varying
outcomes at different biopsy areas. Intra-embryo differ-
ences also applied to sex chromosomes. These outcome
data produced in a single laboratory, nevertheless, sug-
gest a higher degree of repoducability than outcome
comparisons between different laboratories demon-
strated, using different diagnostic platforms.
The small number of so evaluated embryos does not
permit ultimate conclusions about what likely mosaicism
rates in human embryos may be. Here presented data,
Table 1 Comparison of embryo ploidy between two PGS 2.0
assessments





1 A1 1 45, XY, -18b Normal 46, XX
2 A2 1 Complex aneuploidb XY, +10, -18q
A3 2 XY, +11, +16, -21
A4 3 XX, -3q
3 A5 1 46, XY, +3, -11, +15, -14b XX, -2
A6 2 Normal 46XX
A7 3 45, XY, -18
A8 4 Normal 46,XX
4 B1 1 46,XY, +3, -11b 45, XY, -14
B2 2 45, XY, -14
B3 3 45, XY, -14
B4 4 45, XY, -14
5 B5 1 47,XY, +19b 47, XY, +3
B6 2 47, XY, +3
B7 3 47, XY, +3
B8 4 Normal 46, XY
6 C1 1 45, XX, -1b Normal 46, XX
C2 2 Normal 46, XX
C3 3 Normal 46, XX
7 C4 1 47, XY, +19b Normal 46, XY
C5 2 Normal 46, XY
C6 3 Normal 46, XY
8 C7 1 47, XY, +19c Normal 46, XY
C8 2 Normal 46, XY
C9 3 Normal 46, XY
C10 4 Normal 46, XY
9 D1 1 Complex aneuploidc Normal 46, XY
D2 2 47, +18
10 D3 1 Complex aneuploidc 47, XY, +8q, -15, +16
D4 2 46, XY, -15, +16
D5 3 46, XY, -15, +16
D6 4 46, XY, -15, +16
D7 5 46, XY, -15, +16
11 D8 1 46, XX, +14, -15c 46, XX, +14, -15
D9 2 46, XX, +14, -15
D10 3 46, XX, +14, -15
D11 4 46, XX, +14, -15
Pat# patient number, Emb# embryo number; The diagnostic platforms utilized
by the various PGS laboratories are described under Methods: aaCGH, bqPCR
and caray CGH
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do, however, suggest that they are significantly higher
than the 4.8 % rate recently detected by Greco et al.
[13], and more in line with the 2/5 (40 %) range recently
reported by Tiegs et al. [16]. It is also important to con-
sider that these rates may be maternal age-dependent.
Outcome of transfer of (by PGS.2.0) aneuploid embryos
So far 11 women have qualified for transfer of allegedly
aneuploid embryos. Among those, 8 decided to undergo
embryo transfers, and 5 conceived. All 5 have since de-
livered healthy offspring. All pregnancies were con-
firmed to be chromosomally normal with no evidence of
mosaicism. The other three patients did not conceive,
though one experienced a chemical pregnancy and,
therefore, apparently had a short-lived implantation.
Pregnancies are presented in more detail in Table 2.
Here observed rate of 5/8 (62.5 %) of embryo transfers
leading to live birth or normally progressing euploid
pregnancies in a highly unfavorable patient population
with minimal embryo yields in IVF cycles, is unexpect-
edly high. Considering the small patient numbers, per-
centages may, therefore, represent statistical aberrations,
Greco et al. recently also reported a high live birth rate
of 33 % in a similarly unfavorable patient population
after embryo transfers with known mosaic embryos. Lke
we here, they reported no miscarraiges [13]. Eventhough
the combined data from both study groups are still
limited, they, at minimum, contradict that the transfer of
mosaic embryos either impedes implantation or




Considering growing clinical discomfort with the in-
creasing utilization of PGS in IVF and recently arising
questions about accuracy of the procedure, this study
attempted to assess the clinical reproducibility of PGS
results. To bring some clarity to the subject, we dis-
sected 11 embryos previously reported to be aneuploid.
To our surprise, a repeat analysis by a third laboratory
was congruent in only 2/11 (18.2 %) embryos. Indeed,
4/11 embryos (36.4 %) were on repeat evaluation
normal 46, XX and 46, XY, and an additional 2/11
embryos were mosaic, with at least one fragment
reported as normal 46, XX or 46, XY.
Though here investigated embryo numbers were small
and, therefore, do not allow for statistically valid preva-
lence assessments, combined, these numbers suggest a
potential false-positive PGS rate of as high as almost
55 %. Moreover, intra-embryo discrepancies were ob-
served in 50 % (5/10) of embryos suggesting much
higher trophectoderm mosaicism in blastocyst-stage em-
bryos than has previously reported.
Strength and limitations
Greco et al. recently reported only a 4.8 % mosaicism
rate in 3802 blastocyst stage embryos they examined by
single trophectoderm biopsy [13]. That this represents a
significant underestimate is suggested by an earlier study
of Fragouli et al. who reported 32.4 % among 52 investi-
gated blastocyst stage embryos to be mosaic, 30 %
uniformly aneuploid and 42.3 % uniformly euploid [17].
This discrepancy in mosaicism rates can, likely, be
explained by Greco et al. performing only a single troph-
ectoderm biopsy, while Fragoulis et al., like we in this
study, dissected embryos.
A single trophectoderm biopsy usually includes only
approximately 5–6 cells, while the whole trophectoderm
contains at that stage a few hundred. This consideration
alone demonstrates how low the statistical likelihood of
detecting mosaicism (i.e., presence of chromosomally
normal and abnormal cells) is within a single trophecto-
derm biopsy. The likelihood of detecting mosaicism will,
however increase with increasing numbers of biopsies,
both within individual biopsies but also between biopsies
at different areas since those may represent euploid and/
or aneuploid cell lineages of trophectoderm.
Bolton et al. recently demonstrated in a mouse model
that the fate of aneuploid cells in early embryos de-
pends on lineage: aneuploid cells in the fetal lineage
(i.e., inner cell mass) are eliminated by apoptosis,
whereas those in the placental lineage (i.e, trophecto-
derm) demonstrate severe proliferative defects. From
blastocyst stage on aneuploid cells progressively de-
plete, and mosaic embryos have full developmental





1 1 43, XY, -13, -15, -18 Normal birth, 46, XY
2 1 45, XY, -21 Normal birth, 46, XY
3 2a 45, XY, -21
46, XX
Normal birth, 46, XY
4 2b Partial 47, XX,17p11.2-pter
45, XY, -22
Normal ongoing 46, XX
5 2c 47, XY, +22
Partial 45, XY,-1plar-p36, 12
Normal ongoing 46, XY
6 1d 45, XY, -21 Chemical pregnancy
aThis patient, who had undergone PGS for sex selection (desired sex male),
had a 45, XY, -21 and a normal 46, XX female transferred. Since she delivered
a healthy male, the pregnancy had to be the result of the 45, XY, -21 embryo
bTwo embryos were transferred; normal 46, XX per CVS. Pregnancy, therefore,
had to arise from partial trisomic embryo transferred. Currently 20 weeks
cTwo embryos transferred; normal 46, XY per amniocentesis. Embryo leading
to pregnancy unknown; Currently 19 weeks
dChemical pregnancy indicates implantation but not considered a clinical
pregnancy; Ploidy unknown
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potential as long as they contain sufficient euploid cells
[18]. With aneuploid cells preferably seggregating into
the trophectoderm, it appears reasonable to assume
that mosaicism rates will increase with number of
trophectoderm biopsies performed. This was also
suggested by the recent study of Orvieto et al. [12].
Under the assumption of a relatively high mosaicism
rate in trophectoderm, the biological plausibility of PGS
to reliably determine ploidy of embryos with only one
trophectoderm biopsy, therefore, has to be questioned.
The difference in mosaicism prevalence between Greco’s
study on one [13], and Fragouli’s [17] and our study on
the other hand, likely, offers a good estimate of how
much mosaicism is missed by only a single, randomly
chosen trophectoderm biopsy.
As the recent study by Bolton et al. [18] and our study,
however, suggest, Fragouli et al., erred when concluding
that the significant embryo mosaicism they reported was
clinically irrelevant for the accuracy of PGS since only
17 % of mosaic embryos contained also normal cells.
They also appear incorrect when concluding that mosaic
embryos, therefore, only unlikely would be able to lead
to pregnancy and, if they did, pregnancies would, likely,
end in miscarriages [17]. As Bolton et al. demonstrated
in the mouse [18], and Greco et al. [13] and the PGS
Consortium here, mosaic embryos appear to exhibit
rather surprising developmental potential.
Combining Greco’s data [13] with here reported
cases, so far 26 infertile women worldwide received
allegedly aneuploid (and/or mosaic) embryos, resulting
in 11 chromosomally normal live births and/or on-
going clinical pregnancies, for a rather remarkable rate
of 42.3 % of likely live birth in absence of even a single
miscarriage. These unexpectedly high live birth rates
in both studies are that more noteworthy since, as
demonstrated by small number of available embryos,
they involved women with very LFOR. Such patients
iusually produce extremely low live birth and very
high miscarriage rates [1].
The ultimate pregnancy potential from transfer of
mosaic embryos has still to be determined. It, likely, will
depend on patient age, a woman’s FOR and the specific
aneuploidy/mosaicism pattern an embryo presents with.
Studies to obtain this information appear of utmost im-
portance. The International PGS Consortium, therefore,
established a PGS Registry for Transfer of Aneuploid/
Mosaic Embryos, which can be accessed at www.center
forhumanreprod.com or by e-mailing questions to
ykizawa@thechr.com.
Conclusions
Though differences in diagnostic platforms utilized at
different PGS centers may contribute to inter-center
variability of observed results, they do not explain the
intra-embryo variability of 50 % observed in one PGS
center utilizing one platforms for all analyses. Those
have to be the result of embryo mosaicism, and such
mosaicism can obviously lead to false-positive trophecto-
derm biopsies. As first reported by Mastenbroek et al.
[4], and since confirmed by others [6, 7], poor prognosis
patients, who usually produce only small embryo num-
bers, will be especially harmed by false-positive diagno-
ses and the discarding of potentially perfectly normal
embryos. A moratorium on the utilization of PGS In
poor prognosis patients, therefore, appears sensible at
this point.
Finally, mosaic aneuploidy and uniparental disomy
routinely arise from mitotic as well as meiotic events in
human embryos [19]. Even normal human pluripotent
stem cell lines apparently exhibit pervasive mosaic aneu-
ploidy [20]. And the opposite is true as well: aneuploid
embryos have been reported to have given rise to
euploid human embryonic stem cells [21].
Substantial embryonic trophectoderm mosaicism may,
therefore, represent a normal feature of early embryo devel-
opment. Indeed, one could further hypothesize that it may
have developmental purposes in facilitating implantation, as
aneuploidy has been associated with tumor invasion [22].
This hypothesis, indeed, would explain the high prevalence
of here reported mosaicism and the unexpectedly high im-
plantation rates observed by us and Greco et al. [13] in very
adversely selected patients. This hypothesis, of course, turns
upside down the current rational for PGS because it would
suggest potential benefits from embryo selection based on
implantation-enhancing trophectoderm mosaicism.
In summary, this study offers further evidence that the
increasing utilization of PGS requires careful reassess-
ment. Especially poor prognosis patients appear at sig-
nificant risk to actually reduce their pregnancy chances.
But better and even best prognosis patients may also be
negatively affected by PGS, a question we currentlt are
exploring further. The primary reason appears to lie in
higher than previously appreciated mosaicism of human
embryos, which can lead to false positive diagnoses of
aneuploidy and the discarding of potentially normal
embryos.
Here presented data, however, cannot preclude the
possibility that the accuracy of diagnostic platforms
employed by laboratories varies in addition. Here pre-
sented data, however, are not sufficient to comment on
the relative accuracy of various diagnostic platforms, lie
aCGH and NGS, currently utilized as part of PGS.
Combined with above quoted recently published
studies, here presented data demonstrate with unusal
clarity that prudence has to be exercised by practi-
tioners in IVF across all patients when offering PGS
under the hypothesis that the procedure improves
IVF outcomes.
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